{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:34:40Z","timestamp":1793810080513,"version":"4.6.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:41:58Z","timestamp":1786322518000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduced Cumulative Post-Transplant Cyclophosphamide Exposure is Associated with Increased Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-5458","authenticated-orcid":false,"given":"Diego","family":"Soto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Jara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtct.2026.08.003_bib0001","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","article-title":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","volume":"60","author":"Greco","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.003_bib0002","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.003_bib0003","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood.2025030416","article-title":"Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what\u2019s next?","volume":"147","author":"Curtis","year":"2026","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.003_bib0004","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jtct.2025.11.034","article-title":"Low-dose post-transplant cyclophosphamide in haploidentical stem cell transplantation: a systematic review","volume":"32","author":"Shafqat","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"10.1016\/j.jtct.2026.08.003_bib0005","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.21.00471","article-title":"Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update","volume":"39","author":"Griggs","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.003_bib0006","doi-asserted-by":"crossref","first-page":"78.e1","DOI":"10.1016\/j.jtct.2025.09.022","article-title":"Impact of obesity and weight-based chemotherapy dosing adjustments on outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia","volume":"32","author":"Gaskill","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.003_bib0007","doi-asserted-by":"crossref","first-page":"845.e1","DOI":"10.1016\/j.jtct.2022.09.011","article-title":"Comparison of dose adjustment strategies for obesity in high-dose cyclophosphamide among adult hematopoietic cell transplantation recipients: pharmacokinetic analysis","volume":"28","author":"Takahashi","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.003_bib0008","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.htct.2019.01.010","article-title":"Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies","volume":"42","author":"Sarmiento","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.003_bib0009","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2026.08.003_bib0010","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.003_bib0011","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.003_bib0012","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.003_bib0013","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/bcp.14031","article-title":"The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes","volume":"85","author":"Helsby","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2026.08.003_bib0014","unstructured":"eviQ Cancer Treatments Online. Cyclophosphamide (post-transplant) dosing. Available at: https:\/\/www.eviq.org.au\/cellular-therapies\/blood-and-marrow-transplant\/gvhd-prophylaxis\/4428-gvhd-prophylaxis-post-transplant-cyclophospha Accessed 20 June 2026"},{"key":"10.1016\/j.jtct.2026.08.003_bib0015","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41409-026-02928-8","article-title":"Association of ideal body weight\u2013normalized post-transplantation cyclophosphamide dose with chronic GVHD in patients with overweight\/obesity","volume":"61","author":"Nagano","year":"2026","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.003_bib0016","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jha2.962","article-title":"Combination of reduced post-transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft-versus-host disease in human leukocyte antigen-haploidentical peripheral blood stem-cell transplantation","volume":"5","author":"Terao","year":"2024","journal-title":"EJHaem"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:23:39Z","timestamp":1789125819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"alternative-id":["S2666636726006068"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced Cumulative Post-Transplant Cyclophosphamide Exposure is Associated with Increased Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}